Table 1.
Efficacy of TNF-α blockers and IL-12/IL-23 antagonists in the therapy of psoriasis vulgaris (randomized controlled trials)
| Agent | Reference | Trial | Treatment (number of patients) | Results (%) |
|---|---|---|---|---|
| Adalimumab | Gordon et al., 2006 | 12-week RDBPC OLE until week 60 | A 40 mg weekly (50) A 40 mg eow (46) Placebo (52) | PASI 75 at week 12: 80 PASI 75 at week 12: 53 PASI 75 at week 12: 4 |
| Adalimumab (REVEAL) | Menter et al., 2008b | 16-week RDBPC OLE until week 52 | A 40 mg eow (814) Placebo (398) | PASI 75 at week 16: 71 PASI 75 at week 16: 7 |
| Adalimumab (CHAMPION) | Saurat et al., 2008 | 16-week RDBPC | A 40 mg eow (108) MTX (110) Placebo (53) | PASI 75 at week 16: 80 PASI 75 at week 16: 36 PASI 75 at week 16: 19 |
| Briakinumab | Kimball et al., 2008b | 12-week RDBPC | B 200 mg × 1 (30) B 100 mg eow (3) B 200 mg × 4 (30) B 200 mg eow (30) B 200 mg weekly (30) Placebo (30) | PASI 75 at week 12: 63 PASI 75 at week 12: 93 PASI 75 at week 12: 90 PASI 75 at week 12: 93 PASI 75 at week 12: 90 PASI 75 at week 12: 1 |
| Etanercept | Gottlieb et al., 2003 | 12-week RDBPC | E 25 mg twice weekly (57) Placebo (55) | PASI 75 at week 12: 30 PASI 75 at week 12: 2 |
| Etanercept CONSORT | Papp et al., 2005 | RDBPC | E 25 mg twice weekly (196) E 50 mg twice weekly (194) Placebo (193) | PASI 75 at week 12: 34 PASI 75 at week 12: 49 PASI 75 at week 12: 3 |
| Etanercept | Leonardi et al., 2003 | RDBPC | E 25 mg weekly (160) E 25 mg twice weekly (162) E 50 mg twice weekly (164) Placebo (166) | PASI 75 at week 12: 14 PASI 75 at week 12: 34 PASI 75 at week 12: 49 PASI 75 at week 12: 4 |
| Etanercept | Tyring et al., 2006 | 12-week RDBPC | E 50 mg twice weekly (311) Placebo (307) | PASI 75 at week 12: 47 PASI 75 at week 12: 5 |
| Golimumab GO-REVEAL | Kavanaugh et al., 2009a | 24-week RDBPC | G 50 mg q4 wks (146) G 100 mg q4 wks (146) Placebo (113) | PASI 75 at week 14: 40 PASI 75 at week 14: 58 PASI 75 at week 14: 3 |
| Infliximab SPIRIT | Gottlieb et al., 2004 | RDBPC | Infliximab 3 mg·kg−1 (99) Infliximab 5 mg·kg−1 (99) Placebo (51) | PASI 75 at week 10: 72 PASI 75 at week 10: 88 PASI 75 at week 10: 6 |
| Infliximab EXPRESS I | Reich et al., 2005 | RDBPC | Infliximab 5 mg·kg−1 (301) Placebo (77) | PASI 75 at week 10: 80 PASI 75 at week 10: 3 |
| Infliximab | Chaudhari et al., 2001 | RDBPC | Infliximab 5 mg·kg−1 (11) Infliximab 10 mg·kg−1 (11) Placebo (11) | PASI 75 at week 10: 82 PASI 75 at week 10: 73 PASI 75 at week 10: 18 |
| Infliximab EXPRESS II | Menter et al., 2007 | RDBPC | Infliximab 3 mg·kg−1 (311) Infliximab 5 mg·kg−1 (314) Placebo (208) | PASI 75 at week 10: 70 PASI 75 at week 10: 76 PASI 75 at week 10: 2 |
| Ustekinumab PHOENIX 1 | Leonardi et al., 2008 | RDBPC | Ustekin 45 mg (255) Ustekin 90 mg (256) Placebo (255) | PASI 75 at week 12: 67.1 PASI 75 at week 12: 66.4 PASI 75 at week 12: 3.1 |
| Ustekinumab PHOENIX 2 | Papp et al., 2008 | RDBPC | Ustekin 45 mg (409) Ustekin 90 mg (411) Placebo (410) | PASI 75 at week 12: 66.7 PASI 75 at week 12: 75.7 PASI 75 at week 12: 3.7 |
| Ustekinumab ACCEPT | Griffiths et al., 2008 | RDBPC | Ustekin 45 mg (209) Ustekin 90 mg (347) E 2 × 50 mg (347) | PASI 75 at week 12: 67.5 PASI 75 at week 12: 73.8 PASI 75 at week 12: 56.8 |
A, adalimumab; B, briakinumab; E, etanercept; eow, every other week; G, golimumab; OLE, open level extension; q4 wks, every 4 weeks; RDBPC, randomized double-blind placebo controlled trial; Ustekin, ustekinumab.